Ara-290
Peptide derived from the erythropoietin molecule studied for potential tissue-protective and anti-inflammatory effects in select conditions.
This page is for general educational and informational purposes only. It is not medical advice and does not replace professional medical judgment. Always consult a qualified clinician before starting, stopping, or changing any medication or protocol.
Overview
Ara-290 is a small peptide derived from a portion of the erythropoietin (EPO) molecule and has been investigated for potential tissue-protective and anti-inflammatory effects.
Mechanism of action
Ara-290 is designed to engage a so-called tissue-protective EPO receptor complex without stimulating classic erythropoietic pathways, aiming to separate protective effects from red blood cell production.
Indications and use context
Clinical research has focused on neuropathic pain, small fiber neuropathy, and related conditions. Regulatory approvals, if present, are region- and product-specific.
Safety and side effects
Safety observations come from limited clinical trials and may differ from those of traditional EPO products.
Detailed risk information should be obtained from product labeling and up-to-date trial reports.
Pharmacology and dosing considerations
Ara-290 (Cibinetide) is a short-acting peptide requiring daily administration for neuropathic indications.
Route: Subcutaneous injection.
Protocol structure and dosage:- Dosage: 4 mg (4000 mcg) daily.
- Frequency: Once daily.
- Duration: Clinical trials often run for 28 days or longer.
This dosage is derived from Phase 2 clinical trials for sarcoidosis-associated neuropathy.
Formulations and combinations
Catalog listings may present Ara-290 as an injectable peptide, sometimes grouped conceptually with other agents that target inflammatory or neuroprotective pathways.
Research and evidence snapshot
Clinical and preclinical studies have examined pain scores, nerve fiber measures, and inflammatory markers. The overall evidence base remains relatively specialized.
Frequently asked questions
Future FAQs may discuss how EPO-derived peptides differ from full EPO agonists and where they might conceptually fit within neurology and pain management. Answers will remain educational and non-prescriptive.
Comments
Loading comments...
Get the Standard Protocols.
Join 12,000+ researchers. Receive weekly breakdowns of new compounds, safety data updates, and source verification reports.